AMPQuest - Journeying to new horizons in treating drug-resistant infections.

点击翻译按钮获取中文摘要

Context and SignificanceThe World Health Organization (WHO) has identified antibiotic resistance as a major global health threat, impacting not only health but also food security. This issue has led to increased medical costs, longer hospital stays, and a rise in mortality rates, with 1.2 million deaths in 2019 attributed to antibiotic resistance. We are approaching a critical point where common infections and minor injuries might become life-threatening due to drug resistance. This scenario could make routine surgeries highly risky, potentially undermining the achievements of modern medicine.The Potential of Antimicrobial Peptides (AMPs)Antimicrobial peptides (AMPs) are emerging as one of many promising solutions to this crisis. These naturally occurring substances are effective against multi-drug resistant bacteria. The diversity in their modes of action allows for the development of various AMPs into new drugs, potentially bypassing existing bacterial resistance mechanisms.Our Team's Approach and ExpertiseOur team, with over 60 years of combined experience in AMP research and 50 years in AI and data analysis, is at the forefront of this field demonstrated by more than 100,000 citations. Our team possesses the unique capability to synthesize and evaluate thousands of AMPs. We also utilize an advanced AI tool to predict new AMPs from extensive genomic data.Challenges and Opportunities in AI ApplicationWhile AI has advanced in predicting AMP activity, challenges remain, particularly due to variability in existing datasets. These datasets often lack comprehensive information, such as toxicity and effectiveness in human conditions, which are critical for identifying peptides suitable for advanced drug development.Vision and ObjectiveTo overcome these challenges, we are compiling an extensive dataset of thousands of peptides. These will be tested against a multi-drug resistant bacterium under various conditions, generating a rich dataset of 105,000 data points. This initiative will enable our AI system to identify high-value peptide sequences more efficiently, reducing the time and cost of early drug development phases. The savings can then be reallocated to later development stages, enhancing the likelihood of success in clinical trials. Our long-term goal is to extend this research to include all WHO-priority organisms, further refining our AI-driven approach to expedite the development of effective drugs against multi-drug resistant pathogens.ConclusionOur mission is to harness AI to revolutionize antimicrobial drug development. With a skilled team, innovative technology, and a strategic plan, we are well-positioned to make significant contributions to combating drug-resistant infections. This project represents a vital addition to the UK's research landscape.